Astellas Pharma News

Astellas Pharma: Astellas Provides Update on IZERVAY (avacincaptad pegol intravitreal solution) Supplemental New Drug Application

Nov 18 18:00 ET

Astellas Pharma: The latest information on IZERVAY (avacincaptad pegol) partial change approval application in the US

Nov 18 18:00 ET

Astellas Pharma: Confirmation letter

Nov 5 23:52 ET

Astellas Pharma: Half Year Report - Term 20 (2024/04/01 - 2025/03/31)

Nov 5 23:51 ET

Astellas Pharma: Notice Regarding Foreign Exchange Loss

Oct 30 02:00 ET

Astellas Pharma: About recording foreign exchange losses

Oct 30 02:00 ET

Astellas Pharma: Presentation Material for Information Meeting (Q2 YTD/FY2024)

Oct 30 02:00 ET

Astellas Pharma: Supplementary Documents (Q2 YTD/FY2024)

Oct 30 02:00 ET

Astellas Pharma: Financial Results (Q2 YTD/FY2024)

Oct 30 02:00 ET

Astellas Pharma: Supplementary financial information for the 2nd quarter (interim period) of the fiscal year ending March 31, 2025

Oct 30 02:00 ET

Astellas Pharma: Financial results briefing materials for the 2nd quarter (interim period) of the fiscal year ending March 31, 2025

Oct 30 02:00 ET

Astellas Pharma: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [IFRS] (consolidated)

Oct 30 02:00 ET

Astellas Pharma: Astellas Provides Update on Marketing Authorization Application for Avacincaptad Pegol (ACP) in the European Union

Oct 27 19:00 ET

Astellas Pharma: Update on avacincaptad pegol (ACP) European sales approval application

Oct 27 19:00 ET

Astellas Pharma: Astellas’ VYLOY (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer

Oct 20 19:30 ET

Astellas Pharma: VYLOY (zolbetuximab (genetically modified)) approved in the US for the treatment of locally advanced or metastatic gastric adenocarcinoma and esophagogastric junction adenocarcinoma

Oct 20 19:30 ET

Astellas Pharma: Japan’s Ministry of Health, Labour and Welfare Approves PADCEV with KEYTRUDA for First-Line Treatment of Radically Unresectable Urothelial Carcinoma

Sep 24 02:00 ET

Astellas Pharma: Antibody-drug complex Padceb obtains approval for additional indications in Japan for combination therapy with pembrolizumab as primary treatment for unresectable urothelial cancer

Sep 24 02:00 ET

Astellas Pharma: Astellas Receives Approval from the EC for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer

Sep 23 19:30 ET

Astellas Pharma: VYLOY (zolbetuximab) approved in Europe for use in combination with chemotherapy for locally advanced or metastatic gastric adenocarcinoma and esophagogastric junction adenocarcinoma

Sep 23 19:30 ET